Replimune Group (NASDAQ:REPL) Price Target Raised to $18.00

Replimune Group (NASDAQ:REPL) had its price objective upped by BMO Capital Markets from $14.00 to $18.00 in a research note published on Friday morning,Benzinga reports. They currently have an outperform rating on the stock.

A number of other equities analysts have also recently issued reports on REPL. HC Wainwright restated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a report on Friday. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, Roth Mkm assumed coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Trading Up 35.1 %

REPL stock opened at $14.93 on Friday. The firm has a market cap of $1.02 billion, a PE ratio of -4.90 and a beta of 1.19. The firm has a fifty day moving average price of $11.59 and a 200 day moving average price of $9.74. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Sell-side analysts anticipate that Replimune Group will post -3.02 earnings per share for the current fiscal year.

Insider Transactions at Replimune Group

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the completion of the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Several institutional investors have recently bought and sold shares of REPL. Barclays PLC lifted its holdings in Replimune Group by 165.5% during the third quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after buying an additional 98,791 shares during the period. Geode Capital Management LLC lifted its stake in shares of Replimune Group by 17.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock worth $15,657,000 after purchasing an additional 217,308 shares during the last quarter. State Street Corp boosted its position in Replimune Group by 102.1% during the third quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in Replimune Group by 45.5% during the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after purchasing an additional 238,747 shares in the last quarter. Finally, Arizona PSPRS Trust purchased a new position in Replimune Group in the third quarter valued at about $834,000. 92.53% of the stock is owned by hedge funds and other institutional investors.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.